PMI to Launch VEEV Vape Brand in Germany to Compete with Vuse

JTI by 2FIRSTS, edited by Sophia
Apr.09.2024
PMI to Launch VEEV Vape Brand in Germany to Compete with Vuse
PMI launches VEEV vape brand in Germany, competing with Vuse from China and BAT, targeting tobacco users.

According to the German media Nouvelles, Philip Morris International (PMI) has decided to launch its vape brand VEEV in Germany, thereby competing with major Chinese manufacturers as well as the rival product Vuse from British American Tobacco (BAT). Although PMI had already included e-cigarettes in its product line several years ago and sold them in other countries such as Poland, the Czech Republic, and Greece, it had never sold e-cigarettes in Germany.

 

PMI to Launch VEEV Vape Brand in Germany to Compete with Vuse
Disposable product VEEV NOW | Image source: PMI

 

PMI to Launch VEEV Vape Brand in Germany to Compete with Vuse
Pod-system product VEEV ONE | Image source: PMi

 

PMI's Chief Spokesperson, Torsten Albig, stated in a media interview, "We have made extensive and intensive efforts at the government level to ban the sale of disposable e-cigarettes, but to no avail. Therefore, we have decided to enter this market as well."

 

Among teenagers and young people, disposable e-cigarettes are particularly popular. However, the German Federal Ministry of Food and Agriculture appears to be considering banning the use of mint as an ingredient in e-cigarettes in order to reduce the possibility of e-cigarettes gaining market share. However, policymakers in other European countries have responded more uniformly to this issue. For example, countries like France and Belgium will ban the sale of disposable e-cigarettes starting next year.

 

PMI is planning to launch a rechargeable e-cigarette while also selling disposable products. "But this should only be a test product," Albig explained.

 

PMI's current sales policy is to offer a free VEEV charging device with the purchase of three disposable e-cigarettes. This promotion is taking place at participating retailers and the company's IQOS stores. Altria announced that VEEV will be introduced in stores located in major cities that previously only sold heated tobacco products.

 

However, he also admitted that the introduction of e-cigarettes is not just a response to policy loopholes.

 

He pointed out:

 

If we want to achieve our global goals as a group and have over two-thirds of our net revenue contributed by tobacco alternatives by 2030, we cannot afford to leave the German market.

 

In this country, PMI and its IQOS heated tobacco products only occupy a market share of 6%, slightly higher in major cities at just over 10%. Meanwhile, their Marlboro cigarettes hold a 25% market share.

 

PMI hopes to attract smokers with the e-cigarette VEEV and provide competitive pricing: the disposable version will be sold for 7.90 euros, while two refill pods for the reusable system will be priced at 8.90 euros.

 

Although competitors' disposable e-cigarettes are generally priced at ten euros or higher, PMI has decided to challenge their position. Alberg remains calm about the ban on using mint or flavorings in e-cigarettes. He said, "If that's how it is, then so be it. Our products are not meant to attract young people, but to satisfy cigarette smokers who are already accustomed to the taste of tobacco.

 

The World Health Organization has clearly stated that alternative tobacco products are not healthier than traditional tobacco. At the same time, scientists who receive funding from the tobacco industry for research are often suspected of lobbying for the tobacco industry.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
U.S. President Donald Trump has chosen White House health policy aide Heidi Overton to lead the Food and Drug Administration, Bloomberg reported, citing a person familiar with the matter. Overton currently works on health policy at the White House and previously held a senior role at the America First Policy Institute. If confirmed by the Senate, she would take over an FDA that has experienced months of senior-level turnover. The agency regulates products representing roughly one-fifth of U.S. consumer spending, including e-cigarettes, drugs, vaccines and much of the food supply.
News
Aug.19
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
Gallup Tracks Nicotine Pouch Use for the First Time: 11% of U.S. Adults Smoke, 9% Vape and 4% Use Nicotine Pouches
Gallup Tracks Nicotine Pouch Use for the First Time: 11% of U.S. Adults Smoke, 9% Vape and 4% Use Nicotine Pouches
Gallup’s 2026 Consumption Habits survey tracked nicotine pouch use for the first time. The survey found that 11% of U.S. adults reported smoking cigarettes in the past week, 9% reported vaping, and 4% reported using nicotine pouches. Cigarette smoking remained near Gallup’s long-term low, while adult vaping rates stayed relatively stable in recent years.
Market
Aug.25 by 2Firsts Perspectives
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company has begun selling four flavored Vuse Pro pods — Peach, Berry, Watermelon and Fresh Mint — in Ohio and selected other U.S. markets. According to the Vuse U.S. FAQ, Vuse Pro contains approximately 5.0% nicotine by weight, and Vuse Pro pre-filled pods are intended for use with Vuse Alto devices. Reynolds told 2Firsts that product labeling lists an e-liquid capacity of 2.0 mL per pod. The Vuse Alto Power Unit received FDA marketing authorization in 2024, while the new Vuse Pro pods themselves have not received marketing granted orders. The rollout follows the FDA’s May 2026 revision of enforcement priorities for certain unauthorized vaping products with qualifying pending applications.
BAT
Sep.10